Passively administered pooled human immunoglobulins exert il-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis

PLoS Pathogens

Volumn 7, Issue 6, 2011, Pages

  Ramakrishna, Chandran ^a   Newo, Alain N S ^a   Shen, Yueh Wei ^a   Cantin, Edouard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; FC RECEPTOR IIB; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; LY 6C ANTIGEN, MOUSE; LY ANTIGEN; LY-6C ANTIGEN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DEGRANULATION; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SIALYLATION; SURVIVAL; T LYMPHOCYTE; ANIMAL; BRAIN STEM; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MORTALITY; NEUTROPHIL; PATHOGENICITY; PATHOLOGY; TIME; TRANSGENIC MOUSE; VIROLOGY;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

ANIMALS; ANTIGENS, LY; BLOOD-BRAIN BARRIER; BRAIN STEM; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALITIS, HERPES SIMPLEX; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; LEUKOCYTES; MACROPHAGES; MICE; MICE, TRANSGENIC; MONOCYTES; NEUTROPHILS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 79959850012     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002071     Document Type: Article

References (55)

1. Whitley R, (2003) Herpsvirus Infections of the Central Nervous Ssytem. Herpes 11: 1-84.
2. Lundberg P, Welander P, Openshaw H, Nalbandian C, Edwards C, et al. (2003) A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. J Virol 77: 11661-11673.
3. Lundberg P, Ramakrishna C, Brown J, Tyszka JM, Hamamura M, et al. (2008) The Immune Response to Herpes Simplex Virus Type 1 Infection in Susceptible Mice is a Major Cause of CNS Pathology Resulting in Fatal Encephalitis. J Virol 82: 7078-7088.
4. Marques CP, Cheeran MCJ, Palmquist JM, Hu S, Urban SL, et al. (2008) Prolonged Microglial Cell Activation and Lymphocyte Infiltration following Experimental Herpes Encephalitis. J Immunol 181: 6417-6426.
5. Cohen J, (1988) Intravenous immunoglobulin (IVIG) for gram-negative infection-a critical review. J Hosp Infect 12: 47-54.
6. Looney JR, Huggins J, (2006) Use of intravenous immunoglobulin G (IVIG). Best Prac Res Cl Ha 19: 3-25.
7. Negi V-S, Elluru S, SibÉRil S, Graff-Dubois S, Mouthon LUC, et al. (2007) Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action. J Clin Immunol 27: 233-245.
8. Erlich KS, Dix RD, Mills J, (1987) Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin. Antimicrob Agents Chemother 31: 1006-1009.
9. Dalai SK, Pesnicak L, Miller GF, Straus SE, (2002) Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol 8: 35-44.
10. Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
11. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J, (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29: 608-615.
12. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, et al. (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715-722.
13. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, et al. (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179: 5571-5575.
14. Nimmerjahn F, Ravetch JV, (2007) The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204: 11-15.
15. Seite J-F, Shoenfeld Y, Youinou P, Hillion S, (2008) What is the contents of the magic draft IVIg? Autoimmun Rev 7: 435-439.
16. Clynes R, (2007) Protective mechanisms of IVIG. Curr Opin Immunol 19: 646-651.
17. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, et al. (2009) Intravenous immunoglobulins- understanding properties and mechanisms. Clin Exp Immunol 158: 2-13.
18. Nimmerjahn F, Ravetch JV, (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236: 265-275.
19. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV, (2003) Colony-Stimulating Factor-1-Dependent Macrophages Are Responsible for IVIG Protection in Antibody-Induced Autoimmune Disease. Immunity 18: 573-581.
20. Anthony R, Ravetch J, (2010) A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs. J Clin Immunol 30: 9-14.
21. Kaneko Y, Nimmerjahn F, Ravetch JV, (2006) Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation. Science 313: 670-673.
22. Bleeker WK, Teeling JL, Verhoeven AJ, Rigter GM, Agterberg J, et al. (2000) Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95: 1856-1861.
23. Tankersley DL, (1994) Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 139: 159-172.
24. Koelle DM, Corey L, (2008) Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annu Rev Med 59: 381-395.
25. Nimmerjahn F, Ravetch JV, (2006) Fc[gamma] Receptors: Old Friends and New Family Members. Immunity 24: 19-28.
26. Lundberg P, Openshaw H, Wang M, Yang HJ, Cantin E, (2007) Effects of CXCR3 Signaling on Development of Fatal Encephalitis and Corneal and Periocular Skin Disease in HSV-Infected Mice Are Mouse-Strain Dependent. Invest Ophthalmol Vis Sci 48: 4162-4170.
27. Nimmerjahn F, Ravetch JV, (2007) Fc-receptors as regulators of immunity. San Diego Elsevier Academic Press Inc pp. 179-204 Advances in Immunology, Vol 96.
28. Nimmerjahn F, Ravetch JV, (2008) Anti-Inflammatory Actions of Intravenous Immunoglobulin. Annu Rev Immunol 26: 513-533.
29. Smith KGC, Clatworthy MR, (2010) Fc[gamma]RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 10: 328-343.
30. Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ, (2010) Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation 89: 1446-1455.
31. Openshaw H, Cantin EM, (2005) Corticosteroids in herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 76: 1469.
32. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, et al. (2008) Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc. Science 320: 373-376.
33. Sultan Y, Rossi F, Kazatchkine MD, (1987) Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A 84: 828-831.
34. Aschermann S, Lux A, Baerenwaldt A, Biburger M, Nimmerjahn F, (2009) The other side of immunoglobulin G: suppressor of inflammation. Clin Exp Immunol 160: 161-167.
35. Anthony RM, Wermeling F, Karlsson MCI, Ravetch JV, (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 105: 19571-19578.
36. Bazin R, Lemieux R, Tremblay T, St-Amour I, (2004) Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 127: 90-96.
37. Siragam V, Brinc D, Crow AR, Song S, Freedman J, et al. (2005) Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 115: 155-160.
38. Bazin R, Lemieux R, Tremblay T, (2006) Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 135: 97-100.
39. Samuelsson A, Towers TL, Ravetch JV, (2001) Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science 291: 484-486.
40. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV, (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203: 789-797.
41. Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, et al. (2003) IVIg-mediated amelioration of murine ITP via Fc{gamma}RIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102: 558-560.
42. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, et al. (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112: 3303-3311.
43. Lindkvist A, Eden A, Norstrom M, Gonzalez V, Nilsson S, et al. (2009) Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 6: 15.
44. Nandakumar S, Miller C, Kumaraguru U, (2009) T regulatory cells: an overview and intervention techniques to modulate allergy outcome. Clin Mol Allergy 7: 5.
45. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, et al. (2009) Cutting Edge: IL-27 Induces the Transcription Factor c-Maf, Cytokine IL-21, and the Costimulatory Receptor ICOS that Coordinately Act Together to Promote Differentiation of IL-10-Producing Tr1 Cells. J Immunol 183: 797-801.
46. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
47. Simpson TR, Quezada SA, Allison JP, (2010) Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22: 326-332.
48. Lokensgard JR, Cheeran MC, Hu S, Gekker G, Peterson PK, (2002) Glial cell responses to herpesvirus infections: role in defense and immunopathogenesis. J Infect Dis 186 (Suppl 2): S171-179.
49. Lokensgard JR, Hu S, Sheng W, vanOijen M, Cox D, et al. (2001) Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol 7: 208-219.
50. Marques CP, Hu S, Sheng W, Cheeran MC-J, Cox D, et al. (2004) Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia 47: 358-366.
51. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
52. Saraiva M, O'Garra A, (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170-181.
53. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, et al. (2007) Regulatory T Cells Dynamically Control the Primary Immune Response to Foreign Antigen. J Immunol 178: 2961-2972.
54. Phares TW, Fabis MJ, Brimer CM, Kean RB, Hooper DC, (2007) A Peroxynitrite-Dependent Pathway Is Responsible for Blood-Brain Barrier Permeability Changes during a Central Nervous System Inflammatory Response: TNF-{alpha} Is Neither Necessary nor Sufficient. J Immunol 178: 7334-7343.
55. Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, et al. (2007) A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies. Bioconj Chem 19: 89-96.